CymitQuimica logo

CAS 1231930-82-7

:

Bamaciclib Mesylate

Description:
Bamaciclib mesylate is a small molecule inhibitor primarily targeting cyclin-dependent kinases (CDKs), specifically CDK4 and CDK6, which play crucial roles in cell cycle regulation. This compound is utilized in the treatment of certain types of cancers, particularly hormone receptor-positive breast cancer, by inhibiting the proliferation of cancer cells. Bamaciclib mesylate is characterized by its ability to disrupt the cell cycle, leading to cell cycle arrest and apoptosis in malignant cells. The mesylate salt form enhances its solubility and bioavailability, making it more effective for therapeutic use. In terms of physical properties, it is typically presented as a white to off-white solid. The compound's pharmacokinetics, including absorption, distribution, metabolism, and excretion, are essential for determining its efficacy and safety profile in clinical settings. As with many targeted therapies, monitoring for potential side effects and drug interactions is crucial during treatment. Overall, Bamaciclib mesylate represents a significant advancement in targeted cancer therapies, contributing to personalized medicine approaches in oncology.
Synonyms:
  • Abemaciclib Mesylate
Sort by

Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 8 products.